EBMT 2016 | The mechanism of action of inotuzumab ozogamicin
Giovanni Martinelli
• 4 Apr 2016
Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses why inotuzumab ozogamicin is a promising drug for acute lymphoblastic leukemia (ALL) and explains how it targets CD22. Inotuzumab is a calicheamicin-conjugated CD22 antibody and is able to selectively introduce small amount of chemotherapy into CDD22 positive cells.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
